Therapeutic Targets In Breast Cancer Signaling: A Review

被引:17
作者
Obeagu, Emmanuel Ifeanyi [1 ]
Babar, Quratulain [2 ]
Vincent, C. C. N. [3 ]
Udenze, Chikwendu Lawrence [4 ]
Eze, Richard [5 ]
Okafor, Chukwuma J. [6 ]
Ifionu, Bart I. [7 ]
Amaeze, Augustine Amaeze [8 ]
Amaeze, Florence Ngozi [9 ]
机构
[1] Imo State Univ, Dept Med Lab Sci, Owerri, Imo State, Nigeria
[2] Govt Coll Univ, Dept Biochem, Faisalabad, Pakistan
[3] Imo State Univ, Dept Nursing Sci, Owerri, Imo State, Nigeria
[4] Michael Okpara Univ Agr, Dept Univ Hlth Serv, Umudike, Abia State, Nigeria
[5] Madonna Univ Elele, Dept Med Lab Sci, Elele, Rivers State, Nigeria
[6] State Univ Zanzibar, Dept Pathol & Biochem, Zanzibar, Tanzania
[7] Olabisi Onabanjo Univ, Dept Chem Pathol & Immunol, Ogun State, Nigeria
[8] Evangel Univ, Dept Physiotherapy, Akaeze, Ebonyi State, Nigeria
[9] Gregory Univ, Dept Publ Hlth Educ, Uturu, Abia State, Nigeria
关键词
Breast cancer; tumor; apoptosis; cell proliferation; AMERICAN SOCIETY; JAK/STAT PATHWAY; IN-VIVO; PROMOTES; ACTIVATION; CELLS; TUMOR; PROLIFERATION; PROGESTERONE; SUPPRESSES;
D O I
10.9734/JPRI/2021/v33i56A33889
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For women, the most dominant type of cancer is breast cancer and perhaps one of the most recognizedreasons of death. This is a disorder of many distinct traits, many of which are known as positive hormone receptor, human epidermal receptor-2 (HER2+), and three negative breast cancers (TNBC). Drugs that directly target and kill tumors constitute a rapidly-growing form of molecular therapy for cancer patients. Analysis reveals that stable breast tissue cells exhibit receptors which aren't usually present. As a result, it is imperative to cognize the molecular roots of breast cancer and the myriad compromised pathology-related processes and pathways to ensure progresses in early diagnosis and prevention. This study demonstrates essential cellular pathways relevant for breast cancer including improvements in cell proliferation, apoptosis, and hormone balances in breast tissues. On the basis of these notions, we consider how breast cancer is associated to the creation of potentially therapeutic interventions and predictive biomarkers.
引用
收藏
页码:82 / 99
页数:18
相关论文
共 138 条
[61]   C-Phycocyanin exerts anti-cancer effects via the MAPK signaling pathway in MDA-MB-231 cells [J].
Jiang, Liangqian ;
Wang, Yujuan ;
Liu, Guoxiang ;
Liu, Huihui ;
Zhu, Feng ;
Ji, Huanhuan ;
Li, Bing .
CANCER CELL INTERNATIONAL, 2018, 18
[62]   Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists [J].
Johnson, Karen S. ;
Conant, Emily F. ;
Soo, Mary Scott .
JOURNAL OF BREAST IMAGING, 2021, 3 (01) :12-24
[63]   GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling [J].
Khanna, Puja ;
Lee, Joan Shuying ;
Sereemaspun, Amornpun ;
Lee, Haeryun ;
Baeg, Gyeong Hun .
SCIENTIFIC REPORTS, 2018, 8
[64]   CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways [J].
Knutti, Nadine ;
Huber, Otmar ;
Friedrich, Karlheinz .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2019, 451 (1-2) :197-209
[65]   B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model [J].
Koehler, Martin ;
Ehrenfeld, Sophia ;
Halbach, Sebastian ;
Lauinger, Manuel ;
Burk, Ulrike ;
Reischmannl, Nadine ;
Cheng, Shuofei ;
Spohr, Corinna ;
Uhl, Franziska Maria ;
Koehler, Natalie ;
Ringwald, Kathrin ;
Braun, Sandra ;
Peters, Christoph ;
Zeiser, Robert ;
Reinheckel, Thomas ;
Brummer, Tilman .
ONCOGENE, 2019, 38 (08) :1324-1339
[66]   Dramatic dysbalancing of the Wnt pathway in breast cancers [J].
Koval, Alexey ;
Katanaev, Vladimir L. .
SCIENTIFIC REPORTS, 2018, 8
[67]   Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences [J].
Kruger, Dinja T. ;
Beelen, Karin J. ;
Opdam, Mark ;
Sanders, Joyce ;
van der Noort, Vincent ;
Boven, Epie ;
Linn, Sabine C. .
BRITISH JOURNAL OF CANCER, 2018, 119 (07) :832-839
[68]  
Kumar B, 2020, ONCOGENIC MUTATIONS, P1
[69]  
Latorre A, 2020, CHEMOTHERAPY OPTIONS, V2020
[70]  
Li XT, 2018, ANTI-CANCER DRUG, V29, P208, DOI [10.1097/CAD.0000000000000584, 10.1097/cad.0000000000000584]